B. Kim Lee Sim

B. Kim Lee Sim is the President and Chief Scientific Officer of Protein Potential, LLC.

Dr. Sim has led all process development and cGMP manufacture of Sanaria’s aseptic, purified cryopreserved Plasmodium falciparum sporozoite (PfSPZ)-based products that have been assessed in > 36 clinical trials in the U.S. and 10 European and African countries, and will soon enter phase 3 development. She is also president and CSO of Protein Potential, LLC (proteinpotential.com), which she founded in 2003. Protein Potential is currently focusing on a vaccine for shigellosis, ETEC diarrhea, and typhoid fever. Dr. Sim did her undergraduate (B.Sc., Honors, First Class) and graduate studies (M.Sc., Ph.D.) at the University of Malaya. After a post doctoral fellowship in molecular biology at Harvard School of Public Health, she was a research scientist at the Walter Reed Army Institute of Research and adjunct faculty at the Uniformed Services University of Health Sciences, a research assistant professor at Johns Hopkins School of Public Health, and an Expert at NIAID, NIH.

In 1993 she joined EntreMed Inc. as research director of molecular biology, and in 1999 was appointed VP pre-clinical R&D. At EntreMed, Dr. Sim established a development program for anti-angiogenic proteins for cancer therapy, and developed the process that led to cGMP manufacture of tens of kilograms of Angiostatin and Endostatin, anti-angiogenic proteins that entered phase 2 clinical trials. Dr. Sim has extensive experience with yeast and bacterial expression systems and recombineering technologies. She has >148 published scientific papers, and 29 issued and > 7 pending patents.